Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection

References

• AlterMJKruszon-MoranDNainanOVThe prevalence of hepatitis C virus infection in the United States, 1988 through 1994N Engl J Med199934155656210451460
   PubMed Web of Science ®Google Scholar
• Global Burden of HepatitisCWGGlobal burden of disease (GBD) for hepatitis CJ Clin Pharmacol200444202914681338
   PubMed Web of Science ®Google Scholar
• HuKQTongMJThe long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United StatesHepatology1999291311131610094980
   PubMed Web of Science ®Google Scholar
• CornbergMRazaviHAAlbertiAA systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelLiver Int201131Suppl 2306021651702
   PubMed Web of Science ®Google Scholar
• FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med200234797598212324553
   PubMed Web of Science ®Google Scholar
• GhanyMGNelsonDRStraderDBThomasDLSeeff LB; American Association for Study of LiverDAn update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology2011541433144421898493
   PubMed Web of Science ®Google Scholar
• SadlerMDLeeSSRevolution in hepatitis C antiviral therapyBr Med Bull2015113314425680808
   PubMed Web of Science ®Google Scholar
• HerbstDAJrReddyKRSofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infectionExpert Opin Investig Drugs201322527536
   PubMed Web of Science ®Google Scholar
• JacobsonIMGordonSCKowdleyKVSofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsN Engl J Med20133681867187723607593
   PubMed Web of Science ®Google Scholar
• LawitzEGaneEJSofosbuvir for previously untreated chronic hepatitis C infectionN Engl J Med201336967867923944316
   PubMed Web of Science ®Google Scholar
• ZeuzemSDusheikoGMSalupereRSofosbuvir and ribavirin in HCV genotypes 2 and 3N Engl J Med20143701993200124795201
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA/IAS–USARecommendations for testing, managing, and treating hepatitis C2014 [Updated February 24, 2016]. Available from: http://hcvguidelines.orgAccessed March 19, 2016
   Google Scholar
• AlqahtaniSSulkowskiMCurrent and evolving treatments of genotype 1 hepatitis C virusGastroenterol Clin North Am20154482584326600222
   PubMed Web of Science ®Google Scholar
• HerbstDAReddyKRNS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infectionExpert Opin Investig Drugs20132213371346
   PubMed Web of Science ®Google Scholar
• GuMRiceCMStructures of hepatitis C virus nonstructural proteins required for replicase assembly and functionCurr Opin Virol2013312913623601958
   PubMed Web of Science ®Google Scholar
• TanjiYKanekoTSatohSShimotohnoKPhosphorylation of hepatitis C virus-encoded nonstructural protein NS5AJ Virol199569398039867769656
   PubMed Web of Science ®Google Scholar
• TellinghuisenTLMarcotrigianoJGorbalenyaAERiceCMThe NS5A protein of hepatitis C virus is a zinc metalloproteinJ Biol Chem2004279485764858715339921
   PubMed Web of Science ®Google Scholar
• AppelNZayasMMillerSEssential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assemblyPLoS Pathog20084e100003518369481
   PubMed Web of Science ®Google Scholar
• TellinghuisenTLFossKLTreadawayJCRiceCMIdentification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A proteinJ Virol2008821073108318032500
   PubMed Web of Science ®Google Scholar
• BunchorntavakulCReddyKRReview article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infectionAliment Pharmacol Ther20154225827226014906
   PubMed Web of Science ®Google Scholar
• AfdhalNZeuzemSKwoPLedipasvir and sofosbuvir for untreated HCV genotype 1 infectionN Engl J Med20143701889189824725239
   PubMed Web of Science ®Google Scholar
• AfdhalNReddyKRNelsonDRLedipasvir and sofosbuvir for previously treated HCV genotype 1 infectionN Engl J Med20143701483149324725238
   PubMed Web of Science ®Google Scholar
• KowdleyKVGordonSCReddyKRLedipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisN Engl J Med20143701879188824720702
   PubMed Web of Science ®Google Scholar
• CharltonMEversonGTFlammSLLedipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver diseaseGastroenterology201514964965925985734
   PubMed Web of Science ®Google Scholar
• MannsMSamuelDGaneEJLedipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialLancet Infect Dis2016 Epub218
   PubMed Web of Science ®Google Scholar
• BourliereMBronowickiJPde LedinghenVLedipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Lancet Infect Dis201515439740425773757
   PubMed Web of Science ®Google Scholar
• ReddyKRBourliereMSulkowskiMLedipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisHepatology2015621798625846144
   PubMed Web of Science ®Google Scholar
• WylesDPockrosPMorelliGLedipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimensHepatology20156161793179725846014
   PubMed Web of Science ®Google Scholar
• LawitzEFlammSYangJCRetreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeksPresented at: Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the LiverVienna, AustriaApril 22–26, 2015 Abstract O005
   Google Scholar
• NaggieSCooperCSaagMLedipasvir and sofosbuvir for HCV in patients coinfected with HIV-1N Engl J Med201537370571326196665
   PubMed Web of Science ®Google Scholar
• SaabSParkSHMizokamiMSafety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or olderHepatology20166341112111926704693
   PubMed Web of Science ®Google Scholar
• WilderJMJeffersLJRavendhranNSafety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataHepatology201663243744426547499
   PubMed Web of Science ®Google Scholar
• AlqahtaniSAAfdhalNZeuzemSSafety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trialsHepatology201562253025963890
   PubMed Web of Science ®Google Scholar
• (EASL) TEAftSotLRecommendations on treatment of hepatitis C 2015J Hepatol201563119923625911336
   PubMed Web of Science ®Google Scholar